Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure.
Increased circulating endothelial microparticles and carotid atherosclerosis in obstructive sleep apnea.
Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress.
Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ RHO kinase pathways targeted to lipid rafts.
Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis.
The particles, called endothelial microparticles
(EMPs), are shed during the disease process as tiny blood vessels in the lungs, called pulmonary capillaries, are injured and die.
Endothelial microparticles (EMPs) are defined as small vesicles (100 nm to 1 mm in diameter) released from endothelial cells in response to activation or apoptosis by various stimuli (12), with a subset of important membrane proteins and phospholipids from their parent cells.
Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease.
High levels of circulating endothelial microparticles in patients with acute coronary syndromes.
Aggregates of endothelial microparticles and platelets circulate in peripheral blood: variations during stable coronary disease and acute myocardial infarction.
C-reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation.